- Salix's NDA for crofelemer in HIV-associated diarrhea assigned priority review status
- Genentech's BLA for pertuzumab receives priority review status in previously untreated HER2-positive metastatic breast cancer indication
- FDA reviewers questions efficacy of NeurogesX's Qutenza pain patch in proposed new use
- Shire's Vyvanse approved for maintenance treatment in adults with ADHD
- FDA accepts Ziopharm's IND application for oral formulation of Zymafos
- Private FFS MA plans may be linked with higher costs for beneficiaries, GAO report shows
- Pediatric subspecialty telephone consultations may be cost-saving for Medicaid, research reveals
- Use of mental health services greater in health plans with parity in cost sharing, data find
- Public opinions appear split on health care affordability, satisfaction, survey finds
- In Brief: California Supreme Court
Home :: Pediatrics :: Pediatrics Conferences
American Academy of Pediatrics 2008 National Conference & Exhibition
October 11 - 14, 2008 Boston, MA- Symptoms of early, delayed puberty demand close clinical attention, in spite of shifting norms for pubertal onset
- School-based nutrition, exercise intervention program may not maintain BMI decreases through 10 months in overweight students, data indicate
- Office-based education about developmental screening prompts higher use of validated tools, added reimbursement
- Alarm therapy plus desmopressin helps achieve dryness in children with enuresis, study finds
- New evidence challenges need for prophylactic antibiotics, invasive scanning for some young children with UTIs
AACAP 54th Annual Meeting
October 23-28, 2007 Boston, MA- MTA Cooperative Group uses 8-year MTA follow-up data to assess long-term outcomes in children with ADHD
- OROS methylphenidate safely treats adult ADHD, trials show
- Research suggests atomoxetine does not increase smoking in adult smokers with ADHD, but smoking status may predict response to treatment
- Guanfacine XR does not affect daytime sleepiness, increases evening sleepiness in children, adolescents with ADHD, safety analysis shows
- Triple-bead mixed amphetamine salts improves ADHD symptoms in adolescents during 16-hour treatment period, Phase II data indicate
U.S. Psychiatric & Mental Health Congress 2007
October 11-14, 2007 Orlando, FL- Methylphenidate transdermal system linked to deficits in expected growth in children with ADHD
- Guanfacine XR effective, safe in treating ADHD in children, adolescents, researchers report
- Methylphenidate transdermal system shows similar efficacy in male, female children with ADHD, although males may face greater risk of adverse events
- AISRS useful in measuring methylphenidate therapy for adults with ADHD
- Abuse potential with OROS methylphenidate lower than with other methylphenidate formulations
APA 2007 Annual Meeting - ADHD track
May 19-24, 2007 San Diego, CA- Extended-release dexmethylphenidate effective in controlling ADHD in children with combined subtype
- Interpatient pharmacokinetic variability lower in patients receiving lisdexamfetamine as compared with mixed amphetamine salts
- Atomoxetine reduces ADHD symptoms, heavy drinking events in adults with ADHD, alcoholism, findings suggest
- Experts highlight cognitive symptoms of ADHD, efficacy of available treatments
- Personality characteristics among adults with ADHD dependent on substance use disorder, study shows
- GSK submits additional data to FDA for MenHibrix combination vaccine
- FDA expands use of Merck's Isentress for children, adolescents with HIV
- Napo Pharmaceuticals terminates collaboration with Glenmark for breach of contract
- Actavis launches first generic version of Novartis' Ritalin LA
- New formulations of Gilead's Viread approved for use in children with HIV
- Actavis launches first generic version of Novartis' Ritalin LA
- New formulations of Gilead's Viread approved for use in children with HIV
- Napo Pharmaceuticals terminates collaboration with Glenmark for breach of contract
- Number, rate of uninsured children decreased from 2008 to 2010, study shows
- FDA expands use of Merck's Isentress for children, adolescents with HIV
